ISM4808

Product

Last mentioned: Mar 6, 2026

Timeline

  1. Phase I Milestone

    First human subject enrolled and dosed in the Phase I clinical trial.

  2. Phase I Initiation

    First human subject enrolled and dosed in the Phase I clinical trial.

  3. AI Discovery

    Insilico Medicine identifies ISM4808 using its Pharma.AI platform.

  4. Out-Licensing

    TaiGen Biotechnology secures rights for the clinical development of the candidate.

  5. Out-Licensing Deal

    TaiGen Biopharmaceuticals acquires rights for clinical development and commercialization.

  6. Candidate Discovery

    Insilico Medicine identifies ISM4808 using generative AI models.

Stories mentioning ISM4808 2

clinical-trial Bullish

Insilico and TaiGen Advance AI-Derived CKD Anemia Candidate to Phase I

Insilico Medicine and TaiGen Biopharmaceuticals have achieved a major clinical milestone with the first human dosing of ISM4808, an AI-discovered small molecule for Chronic Kidney Disease (CKD) anemia. This Phase I trial marks a critical validation point for Insilico’s Pharma.AI platform and triggers a milestone payment from TaiGen.

3 sources
health-it Bullish

Insilico and TaiGen Advance AI-Derived CKD Anemia Drug to Phase I Trials

Insilico Medicine and TaiGen have successfully enrolled and dosed the first human subject in a Phase I clinical trial for ISM4808, a novel drug candidate for Chronic Kidney Disease (CKD) anemia. The milestone validates the clinical transition of an AI-discovered molecule under a strategic out-licensing agreement.

3 sources